Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Dramatic shift in the infantile hemangioma treatment paradigm at a single institution. Pediatr Dermatol 2013 Nov-Dec;30(6):751-2 PMID: 24117504 PMCID: PMC3984459

Pubmed ID

24117504

DOI

10.1111/pde.12229

Abstract

Historically the first line of treatment for infantile hemangiomas (IHs) has been oral corticosteroids, but because of recent discoveries recognizing the effectiveness of oral and topical beta-blockers, IH management is dynamically changing. With these new treatment options, some physicians are altering the way they manage IHs despite having little evidence-based data on the treatment methods. Highlighting treatment changes at a single large tertiary pediatric referral center, we conclude that despite the numerous studies already published on this topic, more reliable prospective studies are needed to determine the safety, efficacy, and best treatment algorithms for the use of topical and oral beta-blockers for the treatment of IHs.

Author List

Gomulka J, Siegel DH, Drolet BA

Author

Dawn Siegel MD Associate Professor in the Dermatology department at Medical College of Wisconsin




Scopus

2-s2.0-84887625608   11 Citations

MESH terms used to index this publication - Major topics in bold

Adrenal Cortex Hormones
Adrenergic beta-Antagonists
Algorithms
Databases, Factual
Evidence-Based Medicine
Hemangioma
Humans
Infant
Skin Neoplasms
Tertiary Care Centers
jenkins-FCD Prod-331 a335b1a6d1e9c32173c9534e6f6ff51494143916